• Pharma Equity Group reissued its Jan. 1–Jun. 30, 2026 interim report on Aug. 14 because the earlier release omitted the attachment.
• H1 net loss was DKK 2.7 million, versus a restated DKK 17.6 million loss a year earlier.
• Equity stood at DKK 25.8 million at June 30, 2026; cash was DKK 29,000.
• Full-year 2026 guidance was maintained, with revenue seen at DKK 3-8.6 million; EBIT expected at minus DKK 5.8-11.4 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharma Equity Group A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608140515OMX_____CNEWS_DA_GNW1001257614_da) on August 14, 2026, and is solely responsible for the information contained therein.